CN118304207A - A ginsenoside composition, and its preparation method and application - Google Patents
A ginsenoside composition, and its preparation method and application Download PDFInfo
- Publication number
- CN118304207A CN118304207A CN202410476272.2A CN202410476272A CN118304207A CN 118304207 A CN118304207 A CN 118304207A CN 202410476272 A CN202410476272 A CN 202410476272A CN 118304207 A CN118304207 A CN 118304207A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- ginseng fruit
- composition
- glycoside composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 130
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 117
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 105
- 241000208340 Araliaceae Species 0.000 claims abstract description 101
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 101
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 101
- 235000008434 ginseng Nutrition 0.000 claims abstract description 101
- 229930182470 glycoside Natural products 0.000 claims abstract description 68
- 150000002338 glycosides Chemical class 0.000 claims abstract description 68
- ZVTVWDXRNMHGNY-JOGTXEPTSA-N Ginsenoside Rg6 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZVTVWDXRNMHGNY-JOGTXEPTSA-N 0.000 claims abstract description 15
- 230000002087 whitening effect Effects 0.000 claims abstract description 13
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims abstract description 8
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 claims abstract description 8
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims abstract description 8
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims abstract description 8
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 claims abstract description 8
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 43
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 13
- 235000015165 citric acid Nutrition 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- AVXFIVJSCUOFNT-QXPABTKOSA-N (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1 AVXFIVJSCUOFNT-QXPABTKOSA-N 0.000 claims description 8
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 claims description 8
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 8
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 8
- OZTXYFOXQFKYRP-TXRYYSRHSA-N Ginsenoside Rh4 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZTXYFOXQFKYRP-TXRYYSRHSA-N 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 229930014626 natural product Natural products 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 49
- 238000010438 heat treatment Methods 0.000 description 24
- 102000003425 Tyrosinase Human genes 0.000 description 20
- 108060008724 Tyrosinase Proteins 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- QOMBXPYXWGTFNR-KRPFXEAISA-N (20E)-Ginsenoside F4 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QOMBXPYXWGTFNR-KRPFXEAISA-N 0.000 description 10
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 10
- 101710200814 Melanotropin alpha Proteins 0.000 description 10
- 229930182490 saponin Natural products 0.000 description 10
- 150000007949 saponins Chemical class 0.000 description 10
- 235000017709 saponins Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 10
- OZTXYFOXQFKYRP-RISAHGKBSA-N Ginsenoside Rh4 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1 OZTXYFOXQFKYRP-RISAHGKBSA-N 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 6
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 6
- 108010067372 Pancreatic elastase Proteins 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- LDWYLENMYNXSBM-UHFFFAOYSA-N Ginsenoside F4 Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3CC4(C)C(CC(O)C5C(CCC45C)C(=C/CC=C(C)C)C)C6(C)CCC(O)C(C)(C)C36C)C(O)C(O)C1O LDWYLENMYNXSBM-UHFFFAOYSA-N 0.000 description 5
- 230000006750 UV protection Effects 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940068517 fruit extracts Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 3
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 125000003147 glycosyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000036566 epidermal hyperplasia Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 description 2
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PHLXREOMFNVWOH-YAGNRYSRSA-N Ginsenoside Rh3 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(\C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PHLXREOMFNVWOH-YAGNRYSRSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000024148 Herminium Species 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000322338 Loeseliastrum Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000009012 ROS assay kit Methods 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a ginseng fruit glycoside composition, a preparation method and application thereof, and belongs to the technical field of natural products. The ginseng fruit glycoside composition comprises the following components in percentage by mass: ginsenoside R-Rg 3 24.07.07-25.57%, ginsenoside F4.09-27.69%, ginsenoside S-Rg 3 12.35.35-14.08%, ginsenoside Rk 1 8.45.45-9.71%, ginsenoside Rg 6 6.25.25-7.85%, ginsenoside Rg 5 5.13.13-7.88%, and ginsenoside Rd 2.32-4.68%. The ginsenoside R-Rg3、F4、S-Rg3、Rk1、Rg6、Rg5、Rd、Rg2、Rk3、Rh4、Rg1 and Re are selected to be matched into the ginseng fruit glycoside composition, so that the ginseng fruit glycoside composition has the advantages of whitening, resisting wrinkles, resisting ultraviolet and resisting inflammation.
Description
Technical Field
The invention relates to the technical field of natural products, in particular to a ginseng fruit glycoside composition and a preparation method and application thereof.
Background
The ginseng fruit is the mature fruit of ginseng, the main active component of the ginseng fruit is ginsenoside, wherein the content of the ginsenoside Re is up to 30%, and the ginseng fruit has wide biological activity. The total ginsenoside in herba Herminii is about 4 times of that of radix Ginseng, and ginsenoside Re is the monomer saponin with highest content in herba Herminii, and is about 30 times of that of radix Ginseng. Therefore, the prototype saponin is converted into the rare saponin composition by adopting an effective treatment mode, and the prototype saponin has important development significance and economic value in the fields of medicines, foods and cosmetics.
The ginseng fruit extract contains rare saponins which are not contained in various ginseng, has various effects of beautifying, skin care and the like, and is one of important natural raw materials for developing whitening and skin care cosmetics. However, no report on a ginseng fruit glycoside composition rich in rare saponins and a preparation method thereof with the functions of beautifying and protecting skin is known at present.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a ginseng fruit glycoside composition containing various ginseng rare saponins, a preparation method and application thereof, wherein the ginseng fruit glycoside composition has the advantages of whitening, wrinkle resistance, ultraviolet resistance and inflammation resistance.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the invention provides a ginsenoside composition, which comprises the following components in percentage by mass: ginsenoside R-Rg 3 24.07.07-25.57%, ginsenoside F4.09-27.69%, ginsenoside S-Rg 3 12.35.35-14.08%, ginsenoside Rk 1 8.45.45-9.71%, ginsenoside Rg 6 6.25.25-7.85%, ginsenoside Rg 5 5.13.13-7.88%, and ginsenoside Rd 2.32-4.68%.
The ginsenoside R-Rg 3, the ginsenoside F4, the ginsenoside S-Rg 3, the ginsenoside Rk 1, the ginsenoside Rg 6, the ginsenoside Rg 5 and the ginsenoside Rd are selected to be matched into the ginsenoside composition, so that the ginseng fruit composition has the advantages of whitening, resisting wrinkles, resisting ultraviolet and resisting inflammation. Rg 6 and F4 have stronger antioxidant activity than prototype saponins Re, rg 1 and the like, and Rg 3 can inhibit the melanin content in B16-F10 cells by regulating and controlling the expression of MITF and TYR proteins through an ERK signal pathway, so that the ginsenoside composition has the effects of synergistically improving whitening, anti-wrinkle, anti-ultraviolet and anti-inflammatory by matching various rare ginsenosides.
As a preferred embodiment of the ginseng fruit glycoside composition, the ginseng fruit glycoside composition further comprises the following components in percentage by mass: ginsenoside Rg 2 1.66.66-2.45%, ginsenoside Rk 3 1.25.25-1.46%, ginsenoside Rh 4 0.72.72-0.88%, ginsenoside Rg 1 0.51.51-0.69%, and ginsenoside Re 0.22-0.37%. The inventor finds that the micro ginsenoside monomer contained in the ginsenoside composition can further improve the whitening, anti-wrinkle, anti-ultraviolet and anti-inflammatory effects of the ginsenoside composition in the experimental process.
In a second aspect, the present invention provides a method for preparing the above-mentioned ginsenoside composition, comprising the steps of: mixing herba Herminii extract with fruit acid, stirring at 60-120deg.C for 60-180min, cooling, and performing one-step precipitation to obtain herba Herminii glycoside composition. According to the invention, through mixing the ginseng fruit extract with the fruit acid and then heating the mixture for reaction, the hydrolysis efficiency of the prototype ginsenoside in the ginseng fruit extract can be effectively improved, and the ratio of rare ginsenoside in the ginseng fruit composition can be remarkably improved. The invention selects the one-step precipitation method for post-treatment, and has the advantages of simple operation, high speed and high efficiency, energy consumption saving and no loss caused by the participation of organic solvents.
As a preferred embodiment of the method for preparing the ginseng fruit glycoside composition of the present invention, the ratio of ginseng fruit extract to fruit acid is that of ginseng fruit extract: fruit acid= (1-5) kg: (1-2.5) L. Under the preferable proportioning range, the contents of rare ginsenoside and total ginsenoside in the ginsenoside composition are obviously improved.
As a preferred embodiment of the method for preparing the ginseng fruit glycoside composition of the present invention, the ratio of ginseng fruit extract to fruit acid is that of ginseng fruit extract: fruit acid = 1kg: (1.5-2.5) L. Under the preferable proportioning range, the contents of rare ginsenoside and total ginsenoside in the ginsenoside composition are obviously improved.
As a preferred embodiment of the method for preparing the ginseng fruit glycoside composition of the present invention, the fruit acid includes at least one of citric acid, malic acid and grape acid.
As a preferred embodiment of the preparation method of the ginseng fruit glycoside composition, the total content of ginseng saponin in the ginseng fruit extract is 5-95%. The method is suitable for the ginseng fruit extracts with different ginsenoside contents, and can utilize the ginsenoside resources in the ginseng fruit extracts to the greatest extent.
As a preferred embodiment of the method for preparing the ginseng fruit glycoside composition of the present invention, the one-step precipitation method is operated such that the precipitate remains after centrifugation of the product, and the obtained precipitate is washed with water 2 to 4 times.
In a third aspect, the present invention provides the use of the above-described ginsenoside composition in the preparation of a cosmetic.
In a fourth aspect, the invention provides the use of the above-described ginsenoside composition for the preparation of a whitening, anti-uv, anti-wrinkle and/or anti-inflammatory product. The inventor verifies through cell experiments and animal experiments that the ginseng fruit glycoside composition has the effects of inhibiting melanin synthesis, improving skin tissue cutin accumulation, epidermal hyperplasia and traumatic wound caused by ultraviolet, inhibiting collagen degradation and improving active oxygen burst of cells, and has the effects of whitening, resisting ultraviolet, resisting wrinkles and inflammation, and is wide in application range.
As a preferred embodiment of the use of the ginseng fruit glycoside composition of the present invention, the product comprises at least one of food, medicine and health care product.
Compared with the prior art, the invention has the beneficial effects that:
(1) The ginsenoside R-Rg 3, the ginsenoside F4, the ginsenoside S-Rg 3, the ginsenoside Rk 1, the ginsenoside Rg 6, the ginsenoside Rg 5, the ginsenoside Rd, the ginsenoside Rg 2, the ginsenoside Rk 3, the ginsenoside Rh 4, the ginsenoside Rg 1 and the ginsenoside Re are selected to be matched into the ginseng fruit composition, so that the ginseng fruit composition has the advantages of whitening, wrinkle resistance, ultraviolet resistance and inflammation resistance.
(2) According to the invention, through mixing the ginseng fruit extract with the fruit acid and then heating the mixture for reaction, the hydrolysis efficiency of the prototype ginsenoside in the ginseng fruit extract can be effectively improved, the ratio of rare ginsenoside in the ginseng fruit composition is remarkably improved, and the prepared ginseng fruit composition has definite efficacy components and controllable quality, and is suitable for large-scale production. In addition, the invention adopts a one-step precipitation method to carry out post-treatment, and has the advantages of simple operation, high speed and high efficiency, energy consumption saving and no loss caused by the participation of an organic solvent.
Drawings
FIG. 1 shows the effect of different test groups on the melanin content in B16F19 cells in effect example 1, wherein A is untreated with alpha-MSH and B is treated with alpha-MSH;
FIG. 2 shows the effect of different test groups on tyrosinase activity in B16F10 cells in effect example 1, wherein A is untreated with alpha-MSH and B is treated with alpha-MSH;
FIG. 3 shows the effect of different test groups on the expression level of melanin-associated proteins in B16F10 cells in effect example 1, wherein A is MCIR protein, B is Tyrosinase protein, C is p-MITF protein, and D is MITF protein;
FIG. 4 is the effect of different test groups on photodamage to mouse skin in effect example 2, wherein A is the epidermis thickness, B is the dermis thickness, C is the collagen area, and D is the dermis and epidermis thickness;
FIG. 5 is an ultraviolet absorption spectrum of the ginseng fruit glycoside composition and ginseng fruit extract of effect example 3;
FIG. 6 shows the effect of different test groups on the expression level of matrix metalloproteinase in L929 cells in effect example 3, wherein A is MMP-1 and B is MMP-9;
FIG. 7 shows the effect of different test groups on NO release from RAW 264.7 cells in effect example 4;
FIG. 8 shows the effect of different ginsenoside monomers on L929 cell viability in effect example 5;
FIG. 9 is a graph showing the effect of different ginsenoside monomers on the ROS level in L929 cells in Effect example 5;
In the above figures, "" is shown as significant difference (P < 0.05) from the control group, "" is shown as significant difference (P < 0.01) from the control group, "" is shown as significant difference (P < 0.001) from the control group, "#" is shown as significant difference (P < 0.01) from the model group, "#" is shown as significant difference (P < 0.001) from the model group.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples.
Other materials, reagents, etc. used in the following examples and effect examples are commercially available unless otherwise specified.
In the following examples, the methods for detecting the types and contents of ginsenosides in the ginsenoside extract are all HPLC techniques, and specifically include the following steps:
Precisely weighing 20mg of the ginseng fruit glycoside composition sample, placing the ginseng fruit glycoside composition sample in a 10mL volumetric flask, adding 5mL of chromatographic methanol into the flask, performing ultrasonic treatment for 10min, then using the chromatographic methanol to fix the volume to 10mL, and filtering the ginseng fruit glycoside composition solution by using a 0.45 mu m organic microporous filter membrane for later use;
Accurately weighing 1mg of each ginsenoside Rg1、Re、Rg2、Rd、Rg6、F4、Rk3、Rh4、S-Rg3、R-Rg3、Rk1、Rg5 reference substance, placing into a 1mL volumetric flask, adding methanol for dissolving and fixing volume to obtain standard solution, and preparing the above 12 reference substances 1:1, filtering the uniformly mixed solution by using a 0.45 mu m organic microporous filter membrane for later use.
The chromatographic conditions were as follows: the column was Agilent Zorbax Eclipse XDB C (250 mm. Times.4.6 mm,5 μm); the mobile phase is acetonitrile (A) -water (B), and the volume flow rate is 1.0mL/min; the sample injection amount is 20 mu L; the column temperature is 25 ℃; the detection wavelength is 203nm; the elution condition is 0-20min,20% A;20-45min,20-46% A;45-55min,46-55% A;55-60min,55% A;
detecting according to chromatographic conditions, obtaining the peak area of a reference substance, measuring the peak area of the sample corresponding to the retention time, and calculating the content of the component to be detected in the sample according to an external standard method, wherein the ginsenoside content (%) =ax, cr/Ar, cx; ax: sample peak area; cr: the concentration of the reference substance; ar: peak area of the control; cx: sample concentration.
C57 BL/6 mice were purchased from Liaoning long animals Inc. (Liaoning China) and maintained for 12h of light/dark alternating cycles in an SPF-grade environment.
The herba Herminii extract is provided by Jilin Changqing ginseng company, and has a production batch number of 20200901, and the total ginsenoside content is 5-95% by detection.
B16F10 cells were supplied by calico biologicals inc under the product number CL0124.
L929 cells are supplied by Dalian Mey Biol.Co., ltd, under the designation CL0136.
The tyrosinase activity detection kit is provided by Nanjing built biological limited company, and the product number is H310-1-2.
Collagenase activity assay kit is available from Ala Ding Huaxue reagent, inc. under the designation C278962.
The elastase activity assay kit is provided by Aba Ding Huaxue reagent, inc., under the designation E107150.
Ginsenoside R-Rg3, ginsenoside F4, ginsenoside S-Rg3, ginsenoside Rk1, ginsenoside Rg6, ginsenoside Rg5, ginsenoside Rd, ginsenoside Rg2, ginsenoside Rk3, ginsenoside Rh4, ginsenoside Rg1, and ginsenoside Re are all purchased from Chengdu Purui method Co.
The cell activity detection kit is provided by Dalian Mei Lun biological Co., ltd, and the product number is MA0198.
ROS assay kit is provided by Dalian Mei Lun Biolimited, under the designation MA0129.
Example 1
In order to better improve the content of rare ginsenoside in the ginseng fruit glycoside composition, the parameter conditions of the preparation method of the ginseng fruit glycoside composition are optimized, and the specific scheme is as follows:
1. influence of different solid-to-liquid ratios on the ginsenoside content in the ginsenoside composition.
Dissolving herba Herminii extract with different weights, heating to 90-100deg.C, adding citric acid with different volumes, respectively, heating and stirring for 100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the types and contents of ginsenoside in the obtained herba Herminii glycoside composition, wherein the proportions of herba Herminii extract and citric acid, and the types and contents of ginsenoside in the herba Herminii glycoside composition are shown in Table 1.
TABLE 1 influence of different solid-to-liquid ratios on the extract of Herminium (in mass percent)
As shown in table 1, when the ratio of ginseng fruit extract to citric acid is 1kg: (1-2.5) L, the content of rare ginsenoside is greatly increased, and the content of total ginsenoside is also increased, wherein when the ratio of the ginseng fruit extract to the citric acid is 1kg:1.5L, the obtained rare ginsenosides content and total ginsenosides content were highest, indicating 1kg:1.5L is the optimal solid-to-liquid ratio in the preparation method of the ginseng fruit glycoside composition.
2. Influence of different heating times on ginsenoside content in ginsenoside composition
Dissolving 1kg of herba Herminii extract, heating to 90-100deg.C, adding 1.5L of citric acid, heating and stirring for 40-100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the type and content of ginsenoside in the obtained herba Herminii glycoside composition, wherein the heating time and the type and content of ginsenoside in the herba Herminii glycoside extract are shown in Table 2.
TABLE 2 influence of different heating times on the ginsenoside content in the ginsenoside composition (in mass percent)
As shown in Table 2, as the heating time increases, the contents of rare ginsenosides and total ginsenosides in the ginseng fruit composition also increase, and the contents of rare ginsenosides and total ginsenosides in the ginseng fruit composition are higher when the heating time is 60 to 120min, and the contents of rare ginsenosides and total ginsenosides in the ginseng fruit composition are highest when the heating time is 100min, so that 100min is the optimal heating time.
3. Optimization of post-treatment process
(1) One-step precipitation method: dissolving 1kg of herba Herminii extract, heating to 90-100deg.C, adding 1.5L of citric acid, heating and stirring for 100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the type and content of ginsenoside in the obtained herba Herminii glycoside composition, wherein the type and content of ginsenoside in the herba Herminii glycoside extract are shown in Table 3.
(2) Extracting and concentrating an organic solvent: dissolving 1kg of herba Herminii extract, heating to 90-100deg.C, adding 1.5L of citric acid, heating and stirring for 100min, standing in a flask at 90deg.C for precipitation, and cooling to room temperature with tap water at normal temperature;
Adding purified water into a flask to wash precipitate, pouring out the purified water, adding 150-200mL of 95% ethanol to dissolve brown solid at the bottom of the flask, performing rotary evaporation at 80 ℃ until the feed liquid is viscous, transferring the feed liquid into a stainless steel plate, washing the flask with a small amount of ethanol, and transferring the washed liquid into the stainless steel plate;
Evaporating the stainless steel tray with the feed liquid in a water bath at 100 ℃ until the feed liquid does not generate bubbles, transferring into a blast drying oven at 100 ℃ for drying for 3 hours, scraping the materials in the stainless steel tray, powdering, obtaining powder which is the ginsenoside composition, and detecting the types and the contents of the ginsenosides in the obtained ginsenoside composition, wherein the types and the contents of the ginsenosides in the ginsenoside composition are shown in Table 3.
TABLE 3 influence of different post-treatments on ginsenoside in ginsenoside compositions
As shown in Table 3, the ginsenoside composition obtained by the one-step precipitation method has the similar type and content of ginsenoside as those of the ginsenoside composition obtained by the one-step precipitation method, but the one-step precipitation method has the advantages of simple operation, no need of concentration and no participation of organic solvent, can greatly improve the efficiency of the post-treatment process, does not cause the loss of the type and the component of the ginsenoside, and the ginsenoside composition obtained by the one-step precipitation method also contains rare ginsenoside F4 which is not obtained by the post-treatment of the organic solvent, so that the one-step precipitation method is preferred for the post-treatment of the ginseng fruit extract after the acid treatment.
Example 2
The embodiment provides a ginseng fruit glycoside composition and a preparation method thereof, wherein the preparation method of the ginseng fruit glycoside composition comprises the following steps: mixing 1kg of herba Herminii extract with 10-20L of hot water, stirring at 300r/min for 3-5min until herba Herminii extract is dissolved, heating to 90-100deg.C, adding 1.5L of citric acid, heating to 90-100deg.C, stirring at 300r/min for 100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the type and content of ginsenoside in the obtained herba Herminii glycoside composition, with the result shown in Table 4.
The LC-MS technology is adopted to identify the composition of the ginsenoside in the ginsenoside composition, and the specific operation is as follows:
the chromatographic conditions were as follows: the column was CICA MERCK RP (2.0 mm. Times.100 mm,3 μm); the mobile phase is acetonitrile (A) -0.1% formic acid water (B), and the volume flow rate is 0.25mL/min; the sample injection amount is 5 mu L; the column temperature is 35 ℃; the detection wavelength is 203nm;
Gradient elution is adopted, and the elution condition is that 0-3min,19-81％ A;3-6min,22％A;6-9min,30％ A;9-16min,35％ A;16-18min,55％ A;18-22min,55％ A;22-26min,70％ A;26-19min,90％ A;29-29.1min,19％ A;29.1-32min,18％ A;
And (3) carrying out processing analysis on the mass spectrum result by adopting Compound discovery 3.2 software in a full scanning range of 100-1500m/z of the sample in a positive ion mode, and screening a secondary spectrum of molecular ion peaks by combining MS/MS fragmentation of the first 2 ions and structure identification of auxiliary components. The detected mass spectrum fragments and formulations are then compared to a library of compounds established prior to detection for component identification. From these databases, fragmentation patterns are summarized and structures of components having similar structures are deduced therefrom. In addition, for compounds with standards, the compounds were determined by comparison with the retention time, high resolution accurate mass and ion fragments of the control, and the mass spectrum results are shown in table 5.
TABLE 4 detection results of the types and amounts of ginsenosides of different ginsenoside compositions (in mass percent)
| Ginsenoside type | Herba Herminii extract | Example 1 | Example 2 | Example 3 |
| Rg1 | 1.73％ | 0.69％ | 0.61％ | 0.51％ |
| Re | 30.94％ | 0.37％ | 0.22％ | 0.26％ |
| Rg2 | 1.02％ | 2.45％ | 2.34％ | 2.66％ |
| Rd | 7.06％ | 3.43％ | 4.68％ | 3.32％ |
| Rg6 | 0.56％ | 7.77％ | 7.85％ | 6.25％ |
| F4 | 1.42％ | 27.69％ | 27.60％ | 23.09％ |
| Rk3 | 0.35％ | 1.46％ | 1.43％ | 1.25％ |
| Rh4 | 0.01％ | 0.88％ | 0.72％ | 0.79％ |
| S-Rg3 | 0.79％ | 14.08％ | 12.49％ | 12.35％ |
| R-Rg3 | 0.29％ | 24.07％ | 14.01％ | 25.57％ |
| Rk1 | 0.13％ | 9.71％ | 9.47％ | 8.45％ |
| Rg5 | 0.10％ | 6.66％ | 5.13％ | 7.88％ |
As shown in table 4, the mass percentages of the effective components in the ginseng fruit glycoside composition prepared according to the optimal preparation process and different feeding amounts of ginseng fruit extracts are as follows: ginsenoside R-Rg 3 24.07.07-25.57%, ginsenoside F4.09-27.69%, ginsenoside S-Rg 3 12.35.35-14.08%, ginsenoside Rk 1 8.45.45-9.71%, ginsenoside Rg 6 6.25.25-7.85%, ginsenoside Rg 5 5.13.13-7.88%, ginsenoside Rd 2.32-4.68%, ginsenoside Rg 2 1.66.66-2.45%, ginsenoside Rk 3 1.25.25-1.46%, ginsenoside Rh 4 0.72.72-0.88%, ginsenoside Rg 1 0.51.51-0.69%, and ginsenoside Re 0.22-0.37%.
TABLE 5 LC-MS detection results of ginsenoside compositions
As shown in table 5, 15 ginsenoside components were identified in total from the ginsenoside composition, respectively: ginsenoside PPD, ginsenoside Rh3、Rk3/Rh4、Rh2、F1、Rh1、Rg6、Rk1、F4、Rg5、Rg3、Rg2、Rg1、Rd and Re. The theoretical molecular weight and the actual measured value differ by less than 5 ppm. And identifying different types of saponins through the molecular weight, the retention time and the fragment information of the compounds, and analyzing the mass spectrum cracking rule and the structure. The parent nucleus structure of ginsenoside is mainly PPD type and PPT type, the former is characterized in that glycosyl is connected to C-3 and/or C-20, during cleavage, firstly, the glycosidic bond on the C-20 is broken, one molecule of sugar is lost, if disaccharide is adopted, two molecules of sugar are lost together, secondly, glycosyl on the C-3 is sequentially fallen off, and H 2 O molecules are lost in the whole process; the latter is characterized in that the glycosyl is linked to the C-6 and/or C-20 position, and during cleavage, firstly the sugar at the C-20 position is lost, and secondly the sugar at the C-6 position is sequentially released and the H 2 O molecule is lost.
Example 3
The embodiment provides a ginseng fruit glycoside composition and a preparation method thereof, wherein the preparation method of the ginseng fruit glycoside composition comprises the following steps: dissolving 3kg of herba Herminii extract, heating to 90-100deg.C, adding 4.5L of citric acid, heating and stirring for 100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the type and content of ginsenoside in the obtained herba Herminii glycoside composition, and the result is shown in Table 4.
Example 4
The embodiment provides a ginseng fruit glycoside composition and a preparation method thereof, wherein the preparation method of the ginseng fruit glycoside composition comprises the following steps: dissolving 5kg of herba Herminii extract, heating to 90-100deg.C, adding 7.5L of citric acid, heating and stirring for 100min, cooling, centrifuging, removing supernatant, washing the obtained precipitate with 20 times of purified water for 2 times, vacuum drying, pulverizing to obtain herba Herminii glycoside composition, and detecting the type and content of ginsenoside in the obtained herba Herminii glycoside composition, and the result is shown in Table 4.
Effect example 1
In order to verify the whitening effect of the ginsenoside composition, an in vitro experiment is carried out by adopting B16F10 cells, and the inhibiting effect of the composition sample in the embodiment 1 on melanin content, tyrosinase and melanin-related proteins in the B16F10 cells is detected, wherein the specific scheme is as follows:
1. 2X 10 5/mL cells were inoculated into 6-well plates for overnight culture, and then the corresponding groups were treated with various concentrations (1.5, 3, and 6. Mu.g/mL) of the ginsenoside composition obtained in example 2 and alpha-MSH (1. Mu.M, 24 h). After washing the cells with PBS, they were placed on ice, lysed, centrifuged at 12000r for 15min at 4℃and the supernatant was retained for subsequent tyrosinase detection, and the black pellet was dissolved with 1mol/L NaOH (10% DMSO in) at 85℃for 40min, and then the A-value, which was the melanin content, was detected at 405nm using an microplate reader, as shown in FIG. 1.
As shown in FIG. 1, the ginseng fruit extract has almost no effect on melanin content, while the ginseng fruit glycoside composition shows a better melanin inhibiting effect, and at the same time, the ginseng fruit glycoside composition shows a remarkable melanin content inhibiting effect even after induction of melanin-promoting hormone (alpha-MSH) for 24 hours, which indicates that the ginseng fruit glycoside composition of the present invention has a better whitening effect, which is not possessed by the ginseng fruit extract.
2. And (3) taking the protein supernatant to carry out tyrosinase detection, and carrying out tyrosinase detection according to the instruction of the kit. Samples with the same protein concentration were mixed with 180 μl of L-DOPA, the A1 value was detected at 490nm for 10s, then after incubation at 37 ℃ for 3min, the A2 value was accurately detected at 3min 10s, tyrosinase (U/prot) = 90.09 (A2-A1)/Cpr was calculated from the protein concentration, and tyrosinase activity (%) = (experimental group-control group) ×100% was calculated, and the results of tyrosinase activity detection are shown in fig. 2.
As shown in FIG. 2, the B16F10 cells treated by the ginseng fruit composition show a tyrosinase activity inhibition effect superior to that of ginseng fruit extracts after 48 hours, and meanwhile, under the condition of alpha-MSH induction (24 hours), the tyrosinase activity is increased by more than 1.5 times compared with that of a control group, and the ginseng fruit composition can also obviously reduce the tyrosinase activity in the B16F10 cells after the alpha-MSH induction, so that the ginseng fruit composition disclosed by the invention can obviously inhibit the tyrosinase activity.
3. 2X 10 5/mL of B16F10 cells were inoculated in 6-well plates for overnight culture, the cells were first stimulated with alpha-MSH (1. Mu.M) for 24h, and then treated with 1.5, 3 and 6. Mu.g/mL of the ginsenoside composition, respectively, for a further 48h. Cells were collected and washed with cold PBS, lysed with RIPA lysis buffer with protease inhibitors added and well done for 30min on ice, then after centrifugation at 12000rpm for 20min at 4 ℃ and protein supernatants were collected. An equal amount of protein lysate was denatured by heating to 95℃in protein buffer for 10min, and the samples were separated by electrophoresis and transferred to nitrocellulose membrane. The protein membranes were then blocked with 5% nonfat milk powder for 1h and incubated with the corresponding primary antibody (melanin related protein MC1R, tyrosinase, MITF, p-MITF, control beta-actin) overnight at 4℃for 18h with beta-actin as a control for total protein. The results of measuring the level of melanin-related protein expression are shown in FIG. 3, which are obtained by reacting with ECL reagent in the presence of horseradish peroxidase-conjugated secondary antibody and observing the signal in real time in Tanon and 4630.
As shown in FIG. 3, the ginsenoside composition had a significant inhibitory effect on the expression of various melanogenesis proteins, and the expression of MC1R, tyrosinase and MITF was significantly up-regulated after alpha-MSH stimulation, whereas the ginsenoside composition (6. Mu.g/mL) reversed this effect. Furthermore, the treatment of the ginsenoside composition alone also reduced the expression of MC1R, tyrosinase, p-MITF and MITF, indicating that the ginsenoside composition exhibited a significant anti-melanin effect in B16F10 cells.
In conclusion, the ginseng fruit glycoside composition can realize the effect of reducing the melanin content in cells by inhibiting the tyrosinase activity and reducing the expression level of melanin related genes (MC 1R, tyrosinase, p-MITF and MITF), can also realize the inhibition of the tyrosinase activity and the expression level of the melanin related genes under the condition of being induced by melanocyte stimulation, and has excellent whitening effect.
Effect example 2
In order to verify the ultraviolet resistance effect of the ginsenoside composition, the protection effect of the ginsenoside composition obtained in the example 2 on the skin is tested by establishing an ultraviolet irradiation induced skin injury mouse model, and the specific scheme is as follows:
C57 After BL/6 mice were acclimatized for one week, the back hair was shaved on the day prior to the experiment for all groups of mice. The experiments were set up in total with 5 test groups and the specific treatments are shown in table 6. Mice were irradiated once daily on the back with UVB 20mJ/cm 2 for 7 days to establish a model of acute uv skin injury according to table 6. After 12h of the last UVB irradiation, all mice were sacrificed by cervical removal, back skin was peeled off and collected, fixed in 4% paraformaldehyde for Masson staining (Masson), and analyzed for skin dermis thickness, epidermis thickness, total dermis and epidermis thickness, collagen area of the mice, and the statistical results are shown in fig. 4.
TABLE 6 treatment of mice for each test group of the anti-UV experiments
As shown in fig. 4, UVB-irradiated groups showed more inflammatory responses of the mouse skin than normal groups, mainly manifested by excessive accumulation of stratum corneum, hyperplasia of epidermis, and increased thickness, etc., while the pretreatment of the ginseng fruit glycoside composition improved the change of the histomorphology. Meanwhile, in the Masson dyeing result, a traumatic wound is observed on the dermis layer by UVB irradiation, reticular fibers in the reticular layer are greatly proliferated, and the ginsenoside composition obviously restores the collagen distribution in the dermis layer and reduces the fiber quantity densely distributed in the reticular layer.
In conclusion, the ginsenoside composition disclosed by the invention can be used for better improving the cutin accumulation, the epidermal hyperplasia and the traumatic wound of skin tissues of ultraviolet radiation mice, so that the ginsenoside composition disclosed by the invention has an ultraviolet resistance effect, and the ultraviolet resistance effect is better than that of a positive drug VC.
Effect example 3
In order to verify the anti-wrinkle effect of the ginseng fruit glycoside composition, the ultraviolet spectrophotometry is adopted to measure the ultraviolet absorption effect of the ginseng fruit extract and the ginseng fruit glycoside composition obtained in the example 2, and the inhibition effect of the ginseng fruit extract and the ginseng fruit glycoside composition on collagenase and elastase is measured, and meanwhile, the L929 cells after ultraviolet irradiation are adopted to detect the influence of the ginseng fruit glycoside composition on the MMP1 and MMP9 protein expression in the L929 cells after ultraviolet irradiation, the specific scheme is as follows:
Dissolving herba Herminii extract and herba Herminii glycoside composition with chromatographic methanol, respectively diluting to 100 μg/mL, measuring ultraviolet absorption characteristic at 200-400nm, respectively diluting to 1, 2, and 4 μg/mL, and measuring collagenase and elastase inhibition ratio according to kit instruction, wherein ultraviolet absorption spectrum is shown in figure 5, and collagenase and elastase inhibition ratio is shown in table 7.
The protein expression levels of MMP-1 and MMP-9 (the antibodies were changed to MMP-1 and MMP-9 according to the conditions) were determined by the method of step 3 of effect example 1 after L929 cells were irradiated with UVB (600 mJ/cm 2) and then the ginseng fruit glycoside composition was used for drug intervention with Vitamin C (VC) as a positive drug for 24 hours, and the results of the detection of the expression levels of MMP-1 and MMP-9 were shown in FIG. 6.
TABLE 7 Effect of different concentrations of ginseng fruit extract and ginseng fruit glycoside compositions on collagen membrane and elastase
As shown in fig. 5 and table 7, the ultraviolet absorption characteristics of the ginseng fruit glycoside composition were better and the inhibition effects of collagenase and elastase were better than those of the ginseng fruit extract.
MMP-9 is matrix metalloproteinase 9, which acts mainly to degrade collagen in the body. After ultraviolet irradiation, MMP9 protein expression is increased, collagen secreted by human body and cells is reduced, skin aging is caused, as shown in figure 6, the levels of MMP-1 and MMP-9 protein expression after ultraviolet irradiation are increased, and the levels of MMP-1 and MMP-9 protein expression after treatment by the ginseng fruit glycoside composition are obviously reduced, which indicates that the ginseng fruit glycoside composition can inhibit collagen degradation.
In conclusion, the ginseng fruit glycoside composition has better effect of preventing degradation of collagen and elastin secreted by cells, thereby having anti-wrinkle effect.
Effect example 4
To verify the anti-inflammatory effect of the ginseng fruit glycoside composition of the present invention, the effect of the ginseng fruit glycoside composition obtained in example 2 on the release of NO by the LPS-induced RAW 264.7 cells was examined using Lipopolysaccharide (LPS) -induced RAW 264.7 cells, and the specific scheme is as follows:
RAW264.7 cells were treated with LPS as inducer to construct a stable inflammation model, 6 test groups were set up, each treatment being shown in Table 8. RAW264.7 cells in logarithmic growth phase were inoculated into 96-well plates and cultured overnight. After induction for 24h with LPS (final concentration 1. Mu.g/mL), the supernatant was treated with various concentrations of the ginsenoside composition for 24h and assayed for NO content by Griess method. The results are shown in FIG. 7.
TABLE 8 setting of NO content detection for each test group
| Group of | LPS treatment | Tretinoin or ginsenoside composition treatment |
| Control group | Not being treated | Equal volume of solvent |
| Model group | 1μg/mL | Equal volume of solvent |
| Tretinoin group (positive control) | 1μg/mL | 20μg/mL |
| High dose group | 1μg/mL | 80μg/mL |
| Medium dose group | 1μg/mL | 60μg/mL |
| Low dose group | 1μg/mL | 40μg/mL |
As shown in fig. 7, NO levels were significantly increased in the model group compared to the control group, indicating successful construction of the RAW 264.7 cell inflammation model. Compared with a model group, the content of NO in supernatant of cells treated by the ginsenoside composition and LPS is obviously reduced, and the inhibition effect of the ginsenoside composition on the release of NO by RAW 264.7 cells induced by LPS is equivalent to that of positive control tretinoin, so that the ginsenoside composition has a certain anti-inflammatory effect.
Effect example 5
To evaluate the major active ingredients in the ginsenoside composition, the proliferation inhibition activity of the ginsenoside monomer on L929 cells and the H 2O2 -induced redox imbalance of the L929 cells were measured, and the specific scheme is as follows:
1. L929 was cultured in DMEM medium containing 10% FBS, and cell plating was performed when the cell density was as high as 80%. L929 cells were seeded in 96-well plates (cell density 1 x 10 5) and when the cell density was as high as 80%, administration of the ginsenoside monomer control group was performed. Ginsenoside R-Rg3, ginsenoside F4, ginsenoside S-Rg3, ginsenoside Rk1, ginsenoside Rg6, ginsenoside Rg5, ginsenoside Rd, ginsenoside Rg2, ginsenoside Rk3, ginsenoside Rh4, ginsenoside Rg1, and ginsenoside Re are respectively prepared into 1 μm solution, added into 96-well cell plates cultured with L929 cells, and subjected to drug administration and incubation for 24h. After the end of the administration, 10. Mu.L of MTT solution was added to each well, and the culture was continued for 3 hours. Then, the medium in the wells was discarded, 100. Mu.L of DMSO solution was added to each well, and after standing for 20min, the absorbance was measured at 490nm, and the activity of ginsenoside on L929 cells was calculated, and the results are shown in FIG. 8.
As shown in FIG. 8, when the ginsenoside concentration is low (1. Mu.M), the ginsenoside has a promoting effect on the proliferation of L929 cells, wherein the promoting effect of Rk 1、F4、Rg6 and Rd (1. Mu.M) is strong, which suggests that Rk 1、F4、Rg6 and Rd (1. Mu.M) can play a main role in biological activity by promoting the proliferation of fibroblast L929 cells, increasing the secretion of collagen and elastin.
2. Ginsenoside monomers Rk 1、F4、Rg6, rd were co-cultured with L929 cells according to the procedure of step 1, and after 24h incubation, the cellular ROS levels were determined according to the kit instructions, as shown in FIG. 9.
As shown in fig. 9, rg 6, F4 significantly inhibited H 2O2 -induced oxidative stress of L929 cells, and the ability to inhibit ROS production was significantly better than Rk 1, rd, so Rg 6, F4 may be the main active ingredient in the present ginsenoside composition.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The ginseng fruit glycoside composition is characterized by comprising the following components in percentage by mass: ginsenoside R-Rg 3 24.07.07-25.57%, ginsenoside F4.09-27.69%, ginsenoside S-Rg 3 12.35.35-14.08%, ginsenoside Rk 1 8.45.45-9.71%, ginsenoside Rg 6 6.25.25-7.85%, ginsenoside Rg 5 5.13.13-7.88%, and ginsenoside Rd 2.32-4.68%.
2. The ginseng fruit glycoside composition according to claim 1, which comprises the following components in percentage by mass: ginsenoside Rg 2 1.66.66-2.45%, ginsenoside Rk 3 1.25.25-1.46%, ginsenoside Rh 4 0.72.72-0.88%, ginsenoside Rg 1 0.51.51-0.69%, and ginsenoside Re 0.22-0.37%.
3. A method of preparing a ginsenoside composition of claim 1, comprising the steps of: mixing herba Herminii extract with fruit acid, stirring at 60-120deg.C for 60-180min, cooling, and performing one-step precipitation to obtain herba Herminii glycoside composition.
4. The method of claim 3, wherein the ratio of ginseng fruit extract to fruit acid is ginseng fruit extract: fruit acid= (1-5) kg: (1-2.5) L.
5. The method of claim 4, wherein the ratio of ginseng fruit extract to fruit acid is ginseng fruit extract: fruit acid = 1kg: (1.5-2.5) L.
6. The method of any one of claims 3-5, wherein the fruit acid comprises at least one of citric acid, malic acid, and grape acid.
7. The method of claim 3, wherein the total ginsenoside content of the ginseng fruit extract is 5-95%.
8. A process according to claim 3, wherein the one-step precipitation method is operated such that the precipitate remains after centrifugation of the product, and the obtained precipitate is washed with water 2 to 4 times.
9. Use of a ginsenoside composition according to any one of claims 1-2 for the preparation of a cosmetic.
10. Use of a ginsenoside composition according to any one of claims 1-2 for the preparation of a whitening, anti-uv, anti-wrinkle and/or anti-inflammatory product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410476272.2A CN118304207A (en) | 2024-04-19 | 2024-04-19 | A ginsenoside composition, and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410476272.2A CN118304207A (en) | 2024-04-19 | 2024-04-19 | A ginsenoside composition, and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118304207A true CN118304207A (en) | 2024-07-09 |
Family
ID=91732677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410476272.2A Pending CN118304207A (en) | 2024-04-19 | 2024-04-19 | A ginsenoside composition, and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118304207A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
| CN103565679A (en) * | 2012-07-19 | 2014-02-12 | 郑毅男 | Fresh ginseng extract preparation method and application of fresh ginseng extract in cosmetics |
| KR102106018B1 (en) * | 2019-08-09 | 2020-05-15 | (주)지에프씨생명과학 | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage |
| CN112121071A (en) * | 2020-09-29 | 2020-12-25 | 吉林瑞诺科技有限公司 | A product prepared from Ginseng radix |
| CN112294830A (en) * | 2020-09-29 | 2021-02-02 | 吉林瑞诺科技有限公司 | American ginseng leaf product rich in rare ginsenoside |
| CN115990119A (en) * | 2023-02-20 | 2023-04-21 | 三蚁科技(广州)有限公司 | Anti-aging skin care stock solution and preparation method and application thereof |
-
2024
- 2024-04-19 CN CN202410476272.2A patent/CN118304207A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565679A (en) * | 2012-07-19 | 2014-02-12 | 郑毅男 | Fresh ginseng extract preparation method and application of fresh ginseng extract in cosmetics |
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
| KR102106018B1 (en) * | 2019-08-09 | 2020-05-15 | (주)지에프씨생명과학 | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage |
| CN112121071A (en) * | 2020-09-29 | 2020-12-25 | 吉林瑞诺科技有限公司 | A product prepared from Ginseng radix |
| CN112294830A (en) * | 2020-09-29 | 2021-02-02 | 吉林瑞诺科技有限公司 | American ginseng leaf product rich in rare ginsenoside |
| CN115990119A (en) * | 2023-02-20 | 2023-04-21 | 三蚁科技(广州)有限公司 | Anti-aging skin care stock solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4643275B2 (en) | Process for the preparation of Centella Asiatica extract rich in Madecasoside and Terminoloside | |
| Lian et al. | Characterization of a novel polysaccharide from Moutan Cortex and its ameliorative effect on AGEs-induced diabetic nephropathy | |
| JP7414303B2 (en) | Stir-fried homogeneous polysaccharide and its preparation method and application | |
| Sanguigno et al. | Oligosaccharidic fractions derived from Triticum vulgare extract accelerate tissutal repairing processes in in vitro and in vivo models of skin lesions | |
| CN110731919A (en) | Application of Mirabilis jalapa extracts and skin external preparation containing the same | |
| CN112321741B (en) | Plant source component and application thereof in resisting skin photoaging, improving skin renewal and repair capacity and further preparing related cosmetics | |
| CN115531272B (en) | Antioxidant composition derived from alpine plants and preparation method and application thereof | |
| CN114588184B (en) | Herba Saururi extract, and preparation method and application thereof | |
| CN118304207A (en) | A ginsenoside composition, and its preparation method and application | |
| CN112656734A (en) | Preparation method of dandelion extract, extract and application thereof | |
| CN117338681A (en) | Paris polyphylla extract, preparation method and application thereof | |
| CN116889543A (en) | Hair-blacking composition containing plant exosomes, and preparation method and application thereof | |
| CN115414379A (en) | Application of notoginseng polysaccharide SQP20 in preparation of medicine for treating intestinal injury and inflammatory infiltration | |
| CN115969866B (en) | New use of centella asiatica No. 3 extract | |
| CN115212157B (en) | Preparation method and application of natural plant extract compound herbal raw material for whitening, removing freckles and resisting aging | |
| CN118420700A (en) | Ursane type triterpenoid saponin compound and preparation method and application thereof | |
| CN118178434A (en) | New use of centella asiatica No. 2 extract | |
| CN115006305B (en) | Composition with antioxidation effect and preparation method and application thereof | |
| CN118420698A (en) | Ursane type triterpenoid saponin compound and preparation method and application thereof | |
| CN115671167B (en) | Preparation method and application of traditional Chinese medicine composition with acne removing effect | |
| CN115715750B (en) | Osmanthus fragrans extract, preparation method and skin care application thereof | |
| CN113876660B (en) | Plant extract composition, preparation method and application thereof | |
| CN111675772B (en) | Natural component for inhibiting melanin synthesis and application thereof in cosmetics | |
| CN112691063B (en) | Fresh rheum officinale stem juice or extract, preparation method thereof and application thereof in cosmetics | |
| CN114073721B (en) | Preparation and application of vinegar-soaked licorice tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |